Drug Profile
Treprostinil PatchPump - United Therapeutics
Alternative Names: Treprostinil sodium - United Therapeutics; TrevyentLatest Information Update: 13 Mar 2023
Price :
$50
*
At a glance
- Originator SteadyMed Therapeutics
- Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
- Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pulmonary arterial hypertension; Pulmonary hypertension
Most Recent Events
- 13 Mar 2023 Discontinued - Clinical-Phase-Unknown for Pulmonary hypertension in Canada, Middle East, Europe (SC) prior to March 2023
- 13 Mar 2023 Discontinued - Preregistration for Pulmonary arterial hypertension in USA (SC) prior to March 2023
- 10 Feb 2021 Cipher Pharmaceuticals and Verity Pharmaceuticals enter into co-promotion agreement for treprostinil patchPump